Data are needed on long-term effect of natalizumab (NTZ) in relapsing-remitting multiple sclerosis (RRMS).
Objectives:
To evaluate the time of onset of secondary progressive phase in patients with an RRMS treated with NTZ and to investigate predictive factors.
Methods:
TYSTEN is an observational study. Patients starting NTZ between 2007 and 2012 were included and followed up until October 2018. Relapses, Expanded Disability Status Scale (EDSS) scores, and results of brain magnetic resonance imaging (MRI) were collected each year. Data were used to estimate the cumulative probability of several poor outcomes such as secondary progressive multiple sclerosis (SPMS) conversion, EDSS worsening, EDSS 4.0, and EDSS 6.0.
Results:
770 patients were included. The mean follow-up duration was 97 months and the mean time exposure to NTZ was 66 months. At 10 years, the cumulative probability of SPMS was 27.7%. Predictive factors for poor outcomes were a ⩾1-point increase in EDSS score from baseline, new T2 lesion or T1 gadolinium-enhancing lesion, the occurrence of relapse at 1 or 2 years and No Evidence of Disease Activity (NEDA-3; no relapse, no new T2 or T1 gadolinium-enhancing lesions, no progression) was a protective factor.
Conclusion:
In our cohort of patients treated with NTZ, poor outcomes were infrequent and are driven by disease activity.
ConfavreuxCVukusicSMoreauT, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343(20): 1430–1438.
2.
TremlettHZhaoYDevonshireV.Natural history of secondary-progressive multiple sclerosis. Mult Scler2008; 14(3): 314–324.
3.
ManouchehriniaABeikiOHillertJ.Clinical course of multiple sclerosis: A nationwide cohort study. Mult Scler2016; 23: 1488–1495.
4.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
5.
RudickRAStuartWHCalabresiPA, et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. N Engl J Med2006; 354(9): 911–923.
6.
HavrdovaEGalettaSHutchinsonM, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol2009; 8(3): 254–260.
7.
ScalfariANeuhausADaumerM, et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol2013; 70(2): 214–222.
8.
KavaliunasAManouchehriniaAStawiarzL, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler2017; 23(9): 1233–1240.
9.
PoserCMPatyDWScheinbergL, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol1983; 13(3): 227–231.
10.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50(1): 121–127.
11.
PolmanCHReingoldSCEdanG, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”Ann Neurol2005; 58(6): 840–846.
TrojanoMButzkuevenHKapposL, et al. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Mult Scler Relat Disord2018; 24: 11–19.
14.
van PeschVSindicCJFernándezO. Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. Clin Neurol Neurosurg2016; 149: 55–63.
15.
ButzkuevenHKapposLPellegriniF, et al. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry2014; 85(11): 1190–1197.
16.
TremlettHZhaoYJosephJ, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiat2008; 79(12): 1368–1374.
17.
OutteryckOZéphirHSalleronJ, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler J2014; 20(7): 822–829.
18.
RaffelJGafsonARMalikO, et al. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler J2015; 21(14): 1833–1838.
19.
PapeixCVukusicSCaseyR, et al. Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflammation2016; 3(6): e297.
20.
HoP-RKoendgenHCampbellN, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol2017; 16(11): 925–933.
21.
VukusicSRollotFPiqueJ, et al. Did risk stratification modify the incidence of PML in natalizumab-treated MS patients in France?Mult Scler J2018; 24: 981–1026.
22.
WeinshenkerBGBassBRiceGPA, et al. The natural history of multiple sclerosis: A geographically based study 1: Clinical course and disability. Brain1989; 112(1): 133–146.
23.
University of California San Francisco MS-EPIC Team; CreeBACGourraudPA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol2016; 80: 499–510.
24.
RamanujamRHedströmA-KManouchehriniaA, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol2015; 72(10): 1117–1123.
25.
HutchinsonMKapposLCalabresiPA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol2009; 256(3): 405–415.
26.
BermelRAYouXFouldsP, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol2013; 73(1): 95–103.
27.
KapposLKuhleJMultanenJ, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry2015; 86(11): 1202–1207.
28.
BrownleeWJAltmannDRPradosF, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain J. Neurol2019; 142(8): 2276–2287.
29.
KapoorRHoP-RCampbellN, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol2018; 17(5): 405–415.
30.
University of California San Francisco MS-EPIC TeamCreeBACHollenbachJA, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol2019; 85(5): 653–666.
31.
CoretFPérez-MirallesFCGascónF, et al. Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J: Exp Transl Clin2018; 4(2): 2055217318783347.
32.
Baecher-AllanCKaskowBJWeinerHL.Multiple sclerosis: Mechanisms and immunotherapy. Neuron2018; 97(4): 742–768.
33.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376: 221–234.
34.
SormaniMPBruzziP.Can we measure long-term treatment effects in multiple sclerosis?Nat Rev Neurol2015; 11(3): 176–182.
